Study of Tumor Samples From Patients With Lung Cancer

OBJECTIVES:

Primary

- To determine the correlation between c-Met expression, mutation and amplification, with
stage and overall survival in patients with adenocarcinoma (AC) of the lung.

Secondary

- To determine the correlation with epithelial mesenchymal transition (EMT), EGFR
mutations and expression, Kras mutations, p53 mutations, c-CBL protein expression,
mutation, loss of heterozygosity (LOH), DUB3 expression & regulation, and ALK
translocation, with respect to survival.

- To determine the correlation with circulating c-Met and HGF in AC and evaluate
prognostic implications of circulating markers in AC of lung.

- To determine (when available) levels of circulating Met and HGF in serum before and
after surgery.

OUTLINE: This is a multicenter study.

Previously collected tissue samples from patients enrolled in CALGB 140202 are assessed for
mutation analysis of c-Met, EGFR, and K-ras. DNA is examined by PCR, followed by agarose gel
electrophoresis; gene amplification of c-Met is examined by real time quantitative PCR;
met/HF protein in serum is examined by ELISA; and c-Met, EGFR, p53, c-CBL, DUB3 enzyme, and
ALK, and epithelial mesenchymal transition examined by IHC.

Inclusion Criteria:

- Registration to Cancer and Leukemia Group B (CALGB) 140202

- Institutional Review Board (IRB) review and approval at the institution where the
laboratory work will be performed is required

- Informed consent: the CALGB does not require that a separate consent form be signed
for this study

- The subject population to be studied in this protocol includes patients selected
from CALGB 140202; all such patients have signed a written informed consent
document meeting all federal, state, and institutional guidelines as part of
entry into that trial

- All samples to be studied were obtained and stored as part of CALGB 140202; the
material and data obtained from the patient's protocol record will be used to
obtain appropriate clinical information; in no instance will the patient be
contacted directly

- There should be no physical, psychological, social, or legal risks associated
with this study; no invasive procedures are recommended or requested

- All appropriate and necessary procedures will be utilized to maintain
confidentiality; all patients who have had samples submitted for analysis will
have their CALGB study number used to identify specimens

- This study does not require direct patient contact and no specific risk or
benefits to individuals involved in the trial are anticipated; it is likely,
however, that the information gained will substantially help similar patients in
the future